Importantly, harmine inhibited the phosphorylation of a specific substrate by DYRK1A in cultured cells with a similar potency to that observed in vitro (IC 50 =48 nM), without negative effects on the viability of the cells. Overexpression of the DYRK1A gene on chromosome 21 has been implicated in the altered neuronal development observed in Down syndrome. Here, we show that harmine interferes with neuritogenesis in cultured hippocampal neurons. In summary, our data show that harmine inhibits DYRK1A substrate phosphorylation with higher potency than tyrosine autophosphorylation, and provide evidence for a role of DYRK1A in the regulation of neurite formation. to microcephaly, the human DYRK1A (dual-specificity tyrosine phosphorylationregulated kinase 1A) gene has been implicated in the neurodevelopmental alterations associated with these syndromes [1, 2, 3, 4] . DYRK1A (also called MNB) is the ortholog of the Drosophila mnb (minibrain) gene that is involved in neurogenesis [5] . Diverse evidence has also related mammalian DYRK1A to neuronal differentiation processes [6, 7, 8, 9, 10, 11, 12, 13] . Supporting the pathogenetic role of an imbalance in DYRK1A gene dosage, consistent alterations in neurogenesis and neuronal structure were observed in mouse models with a selective gain or partial loss of function of Dyrk1A (as reviewed in ref. [14] ).
In addition to its function in neuronal development, recent evidence has also implicated DYRK1A in the pathology of neurodegenerative disorders such as Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease. DYRK1A has been shown to promote the formation of pathophysiological hallmarks of these diseases via direct phosphorylation of their most abundant components, such as tau in neurofibrillary tangles [11, 15, 16] , α-synuclein in Lewy bodies [17] and amyloid β precursor protein (APP) [18] . In addition, we have recently shown that DYRK1A phosphorylates septin 4 [19] , a protein that has been associated with neurofibrillary tangles in Alzheimer's disease and with α-synuclein-positive cytoplasmic inclusions in Parkinson disease. Protein levels, as well as the catalytic activity, of DYRK1A are increased in central neurons in Down syndrome and Alzheimer's disease [11, 15, 20] .
These findings raise the possibility that the formation of these protein aggregates in neurodegenerative diseases can be prevented or delayed by pharmacological inhibition of the excessive activity of DYRK1A. DYRK1A contains a conserved tyrosine residue in the activation loop of the catalytic domain (Tyr321) whose phosphorylation is required for full catalytic activity [21] . In contrast to related kinases, such as the MAP-kinase family, the activating tyrosine phosphorylation of DYRK family kinases is not catalysed by upstream kinases but occurs through autophosphorylation [21, 22] . For the Drosophila kinases dDYRK2 and MNB, this autophosphorylation has been shown to take place during translation [23] . Thus, mature DYRK kinases are incapable of catalyzing their tyrosine autophosphorylation [22, 24] . This implies that inhibitors of the one-off autophosphorylation reaction should irreversibly inhibit DYRK kinases. Lochhead et al. [23] have distinguished two classes of DYRK inhibitors, those that target only the mature kinase, and those that also inhibit the tyrosine autophosphorylation of the translational intermediate. Although purvalanol A has been shown to block tyrosine autophosphorylation of dDYRK2 [23] , its proposed irreversible effect has not yet come under scrutiny.
Several compounds originally designed to target other protein kinases also inhibit DYRK1A, e.g. the CDK inhibitors roscovitine and purvalanol A [25] . New synthetic DYRK1A inhibitors were rationally developed as potential therapeutic agents to target learning and memory deficits in Down syndrome, but their selectivity
has not yet been tested against a broad panel of kinases [26, 27] . Two plant compounds, epigallocatechin-gallate (EGCG) and harmine, have been identified as highly specific DYRK inhibitors in the course of systematic surveys of kinase inhibitors [25, 28] . EGCG, the major polyphenolic compound of green tea, has been used in studies of DYRK1A [24, 29] , but its usefulness in cell and animal experiments is compromised by complicated pharmacokinetic properties and poor bioavailability [30, 31] . Harmine is an alkaloid originally isolated from the South American vine Banisteriopsis caapi and has previously been characterized as a potent inhibitor of monoamine oxidase A (MAO-A) [32] .
In this study we have determined the potency and specificity of harmine towards DYRK1A compared to other members of the DYRK family and analyzed in vitro and in cultured cells whether harmine discriminates between substrate phosphorylation and tyrosine autophosphorylation of DYRK1A. Finally, we have taken advantage of harmine to assess the possible involvement of DYRK1A in neurite formation using cultured neurons.
Results

Harmine inhibits DYRK1A more potently than other members of the DYRK family
The kinase selectivity screen of Bain and colleagues [28] included DYRK1A, DYRK2 and DYRK3 but not DYRK1B or DYRK4. We have therefore compared the specificity of harmine towards DYRK1A and related DYRK-kinases in in vitro kinase assays and determined the IC 50 values for recombinant DYRK1A, DYRK1B, DYRK2, DYRK4 and the Drosophila homologue of DYRK1A/DYRK1B, minibrain (MNB). As shown in Fig. 1C , harmine inhibited DYRK1A with the highest potency (IC 50 value = 33 nM). Notably, the closely related isoform, DYRK1B (Fig. 1B) was inhibited with approximately 5-fold lower potency than DYRK1A (IC 50 = 165 nM, see Table 1 ) and approximately similar potency to Drosophila MNB (IC 50 = 149 nM, Fig. 1D ), which also exhibits 85% sequence identity with DYRK1A in the catalytic domain. IC 50 values for DYRK2 and DYRK4 were found to be more than 10-fold higher (2 µM and 74 µM). 
The effects of harmine in cell culture
We next analyzed the effect of harmine on cell viability, because it has previously been characterized as a cytotoxic agent [33] . Viability assays with HeLa and HEK293 cells showed that harmine displays minimal toxicity at concentrations up to 1 µM ( Fig. 2A) . Thus, concentrations of harmine that cause near complete inhibition of DYRK1A in vitro do not affect cell viability. Similar to the results reported by Song et al. [33] , toxic effects were observed at harmine concentrations greater than 3 µM. Significant reduction of cell viability by high harmine concentrations (10 µM) was first detectable after 30 h (Fig. 2B) . Continuous monitoring of cell growth by revealed that inhibitory effects of 3.3 µM and 10 µM harmine were first detectable after 12-15 h of treatment (Fig. 2C) , consistent with the notion of Song et al. [33] that high concentrations of harmine block cell proliferation by inhibiting cyclin dependent kinases.
To examine whether harmine could inhibit DYRK1A activity in cells, we investigated the effect of harmine on the DYRK1A-catalysed phosphorylation of its known substrate, the splicing factor SF3B1. We have previously shown that DYRK1A phosphorylates SF3B1 at Thr434, and that shRNA-mediated knockdown of DYRK1A suppresses the phosphorylation of Thr434 [34] . HeLa cells were transiently transfected with an expression vector encoding a fusion protein of green fluorescent protein (GFP) and the N-terminal part of SF3B1 (amino acids 1-492) and treated with varying concentrations of harmine. Western blot analysis showed that harmine reduced the level of phospho-Thr434 in SF3B1 in a concentration-dependent manner (Fig. 3A) . Quantitative evaluation of three independent experiments yielded an IC 50 value of 48 nM (Fig. 3B ). This experiment shows that harmine is a highly cellpermeant inhibitor of DYRK1A. Next, we asked whether harmine could not only inhibit the activity of the mature form of DYRK1A (as in the in vitro assays), but also prevent its activation by tyrosine autophosphorylation. To address this question, we used a HEK293 subline that overexpresses GFP-DYRK1A stably under the control of a doxycyclinregulatable promoter [19] . Immediately after induction with doxycyclin, the cells were (or were not) treated with harmine for 48 h. GFP-DYRK1A was immunoprecipitated and subjected to kinase assays and Western blot analysis (Fig. 4) . Harmine was applied at a concentration of 4 µM, at which concentration the phosphorylation of Thr434 in the endogenous SF3B1 in HEK293 cells was completely blocked (Fig. 4B ).
In contrast, harmine treatment only modestly inhibited tyrosine phosphorylation of GFP-DYRK1A (Fig. 4A) . Furthermore, the catalytic activity of GFP-DYRK1A that was isolated from harmine treated cells did not differ significantly (p = 0.09) from that purified from untreated cells (Fig. 4C ). This result indicates that harmine does not inhibit the activation of DYRK1A by tyrosine autophosphorylation at a concentration that leads to the complete inhibition of DYRK1A activity towards SF3B1.
The effect of harmine on tyrosine autophosphorylation in vitro
Lochhead et al. [23] had employed a cell free translation system based on rabbit reticulocyte lysates to determine the differential effects of inhibitors on tyrosine autophosphorylation of Drosophila DYRK2. Our attempts to reproduce this result for mouse DYRK1A failed, probably because the amounts of in vitro-translated protein were too small for the immunochemical detection of phosphotyrosine (data not shown). Much higher amounts of FLAG-DYRK1A were produced when we used 21 (Fig. 5A) . Harmine was applied at a concentration of 1 µM, which inhibited the catalytic activity of DYRK1A by more than 90%, both in vitro (Fig. 1 ) and in HeLa cells (Fig. 3) . It was also applied at 10 µM to achieve maximal inhibition. For comparison, the effect of purvalanol A was analyzed in parallel because this inhibitor was shown by Lochhead et al. [23] to inhibit the tyrosine autophosphorylation of Drosophila DYRK2 at a concentration of 50 µM. Both harmine and purvalanol A caused a reduction of immunoreactive phosphotyrosine in FLAG-DYRK1A, although tyrosine autophosphorylation was only partially blocked even at the higher concentrations of the inhibitors (Fig. 5B) . The catalytic activity of FLAG-DYRK1A after purification from the reaction mixture was unaffected by the preceding treatment with harmine and it was marginally reduced after treatment with purvalanol A (Fig. 5C ).
In vitro translation in a bacterial expression system
In vitro translation in eukaryotic cell-free systems allowed us to study the effect of harmine on the co-translational tyrosine autophosphorylation of the DYRK kinases.
However, such reaction mixes are still highly complex systems containing other protein kinases and proteins that may indirectly affect the enzymatic properties of DYRK1A. Therefore, we took advantage of the newly developed PURExpress in vitro-translation system, which relies on well-defined and purified components from E. coli to reconstitute cell-free translation [35] . For these experiments, we generated a bacterial expression construct that produced only the catalytic domain of DYRK1A (DYRK1Acat), and thus lacked most of the tyrosines in the N-terminal domain. In particular, DYRK1Acat does not include Tyr111, which we have previously identified as a major autophosphorylation site of recombinant DYRK1A in E. coli [21] . First, we 
The effect of harmine on neurite formation in hippocampal neurons
To assess the physiological consequences of the inhibition of the protein kinase activity of DYRK1A by harmine in the nervous system, we set out to test its effects on neuronal differentiation, a complex sequence of processes in which MNB and DYRK1A have been previously implicated (see Introduction). Several observations point to a role of DYRK1A in neuritogenesis, an early differentiation process, although no direct evidence has been so far provided (see Discussion for details). Accordingly, we decided to use harmine to assess this new possible function 21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Nevertheless, we noticed that the inhibitory effect of harmine was statistically significant only for neurons with 4 or less neurites when data of control and harminetreated neurons were paired for independent Student´s t test analysis (Fig. 8A ). This may suggest that harmine was less effective in neurons that were already developing neurites at the time when harmine was added to the culture. Specificity is a serious concern whenever inhibitors are used to dissect the biological functions of a given protein kinase, as unwanted effects on other kinases may lead to erroneous conclusions. Here we show that harmine displays exceptional specificity towards DYRK1A even in comparison with the other members of the DYRK family. The IC 50 -value for DYRK2 (2 µM) was about 50-fold higher than for DYRK1A (33 nM), whereas DYRK4 was largely resistant to harmine (IC 50 > 50 µM).
Our result for DYRK2 matches quite well with the published data of Bain et al. [28] who measured IC 50 values of 0.9 µM (at 50 µM ATP) for DYRK2 and 0.8 µM for its closest neighbor, DYRK3. Five-fold higher concentrations of harmine were required for the inhibition of DYRK1B or MNB than for DYRK1A (Table 1) , although these kinases exhibit 85% sequence identity with DYRK1A in the catalytic domain.
Although important, this difference between the inhibitory potencies of harmine towards DYRK1A and DYRK1B is too small to fully discriminate pharmacologically between the cellular effects of these kinases. Nevertheless, at a concentration of 1 µM, harmine inhibits DYRK1A, DYRK1B by >90% but only marginally affects the activities of other DYRK family members. Side effects caused by inhibition of other protein kinases are unlikely because Bain et al. [28] reported modest inhibition by harmine only for CK1 (IC 50 = 1.5 µM) and PIM3 (IC 50 = 4.3µM), among 69 kinases On the other hand, the antidiabetic effect of harmine as an inducer of PPARγ expression required concentrations higher than 1 µM [39] . Hence, this effect of harmine is necessarily accompanied by a near-maximal inhibition of DYRK1A.
Interestingly, mean peak plasma levels of 0.54 µM harmine have been determined in volunteers after ingestion of the hallucinogenic hoasca beverage within a ceremonial context [40] . Hoasca is a decoction of Banisteriopsis caapi and dimethyltryptaminecontaining plants, and is regularly used in shamanic rituals and South American sects for its visionary effects. Thus, regular users of hoasca are repeatedly exposed to levels of harmine that cause a substantial inhibition of DYRK1A. Similar doses of harmine to those ingested by hoasca users (about 250 mg, [40] were used at the end of the 1920s for the treatment of postencephalitic Parkinsonism [41] .
A point of particular interest to note in respect of the inhibitors of DYRK kinases is the potential capacity to block autophosphorylation of the critical activationloop tyrosine, which is expected to irreversibly inhibit the kinase [23] . We found no 13 reduction of phosphotyrosine in GFP-DYRK1A that was isolated from harminetreated HEK293 cells, and the catalytic activity was unaltered when compared to GFP-DYRK1A from untreated cells (Fig. 4) . In the same cells, phosphorylation of SF3B1 at Thr434 was completely blocked by treatment with harmine. Of note, DYRK1A autophosphorylation at Ser520 in HEK293 cells was almost completely inhibited by harmine treatment at a concentration of 1 µM [36] . Taken We consider the results obtained with the PURExpress system to be the most informative concerning the inhibitory effect of harmine on tyrosine autophosphorylation. This translation system is reconstituted from isolated E. coli to purvalanol A is not surprising, given that these kinases belong to distinct branches of the DYRK family of protein kinases (Fig. 1B) .
Extensive evidence relates mammalian DYRK1A and its orthologues (Drosophila MNB, chicken MNB) to neuronal differentiation processes. In particular, the fact the MNB/DYRK1A is localized in the growing dendritic tree of diverse vertebrate central neurons [7, 12] strongly suggests a role in the regulation of dendrite Dyrk1A exhibit increased size [42] . Nevertheless, there are also some indications that MNB/DYRK1A might be involved in earlier steps of neuronal differentiation. For instance, upregulation of MNB/DYRK1A expression has been shown to precede the onset of dendrite formation in several neuronal populations [7, 12] . It has also been reported that DYRK1A is markedly upregulated during the bFGF-induced differentiation of a hippocampal progenitor cell line and that blockade of this upregulation significantly inhibits neurite formation [6] . Moreover, a recent RNAi screen in Drosophila identified MNB as a regulator of cell protrusions in cell lines derived from the central nervous system [43] . Together, these data point to the possible involvement of DYRK1A on the regulation of neurite formation. Accordingly, we have here shown that harmine inhibited neuritogenesis in cultured hippocampal neurons. Thus, our results provide the first evidence for a role of DYRK1A on neurite formation in bona fide neurons. Future research should shed light upon the molecular mechanisms underlying this novel DYRK1A function.
In conclusion, the present data show that harmine is a potent and selective inhibitor that can be used as a pharmacological tool to interfere with functions of the protein kinase DYRK1A in cultured neurons. Although the exploration of its therapeutic options using Down syndrome animal models are in principle compromised by its MAO inhibitory effect, harmine may serve as a lead compound to develop a novel DYRK1A inhibitor devoid of MAO inhibiting activity. 
Materials and Methods
Cell culture and transfection
HeLa cells were cultured in RPMI-1640 medium (PAA Laboratories, Pasching, Austria) supplemented with 10% fetal calf serum (PAA) at 37°C in a humidified 5% CO 2 atmosphere. For controlled overexpression of DYRK1A, we used a stably transfected HEK293 cell clone expressing GFP-DYRK1A under the control of a tetracycline-regulated promoter (HEK-tetGFP-DYRK1A) [19] . HEK293 cells were maintained in DMEM High Glucose (4.5 mg/l) (PAA) supplemented with 10% fetal calf serum. Expression of GFP-DYRK1A was induced with 2 µg/ml doxycycline. 
Antibodies
The rabbit antibody for the specific detection of phosphorylated Thr434 in SF3B1
(pThr434) has been described previously [34] . Sheep anti-DYRK1A antibody raised against bacterially expressed GST-DYRK1A-∆C was kindly provided by Philip Cohen (MRC Protein Phosphorylation Unit, Dundee, Scotland, UK). The following antibodies were purchased from commercial sources: mouse monoclonal pan-specific 
Bacterial expression of recombinant proteins
Plasmids for the bacterial expression of glutathione S-transferase-(GST-)DYRK1A-∆C, GST-DYRK1B-p69, and GST-DYRK2 have been described previously [21, 44, 45] (UniProt acc. Nos. Q63470, Q9Y463, Q92630). The Drosophila minibrain kinase (MNB)(P49657) was expressed as a fusion protein with maltose binding protein (MBP) [45] . GST and MBP fusion proteins were expressed in E. coli and affinity purified For all DYRK kinases, one unit of kinase activity was defined as the amount of enzyme that catalyzed the phosphorylation of 1 nmol DYRKtide per min at 30°C. His 6 -tagged SF3B1-NT was prepared as described previously [34] . (Whatman, Maidstone, UK), followed by washing in 5% phosphoric acid (10 times for 10 minutes each time), and subsequent liquid scintillation counting.
In vitro protein kinase assays
Viability assay
Effects of inhibitors on cell proliferation and viability were determined with a 
Real-time cell-electrode impedance measurements
We used the xCELLigence System (Roche Diagnostics, Penzberg, Germany) for real-time monitoring of harmine cytotoxicity. Two hundred microliters of growth medium were added to the wells of an E-plate for background measurements. HeLa cells were seeded in triplicate wells at a number of 3,000 and 5,000 cells/well in 200 µl. After 24 hours, 100 µl of the medium was removed, harmine was added to the respective wells in a volume of 100 µl of fresh medium The continuous impedance measurement was recorded and converted to a cell index. Results were analyzed using RTCA Software 1.1 (Roche Diagnostics). 
Assay of SF3B1 phosphorylation by DYRK1A in HeLa cells
Harmine treatment of cultured hippocampal neurons
Cultures of embryonic mouse hippocampal cells were prepared following standard protocols [46] . In brief, hippocampi from E18 mouse embryos were finely dissected in Hank's Balanced Salt Solution (HBSS). After a mild and short incubation with trypsin in HBSS, the cells were dispersed in DMEM (Invitrogen) medium supplemented with 10% fetal bovine serum and antibiotics (penicillin and streptomycin). After counting and a viability test employing trypan blue, the cells were plated on poly-L-lysine coated 12 mm coverslips at a density of 25,000 viable cells/cm Immunocomplex kinase assay of GFP-DYRK1A and analysis of tyrosine phosphorylation HEK-tetGFP-DYRK1A cells were seeded onto 10-cm plates. Two hours after seeding, expression of GFP-DYRK1A was induced by adding 2 µM doxycycline, and the cells were then treated with 0.5-4 µM harmine. Two days later, cells were lysed under non-denaturating conditions using 1 ml of native lysis buffer per plate (50 mM Hepes pH 7.4, 150 mM NaCl, 25 mM NaF, 2 mM EDTA, 30 mM sodium pyrophosphate, 0.5% Igepal CA-630 (Sigma), 1 mM sodium vanadate, 10 µg/ml pepstatin, 10 µg/ml leupeptin, 1 mM PMSF, 10 µg/ml aprotinin) on ice. The samples were spun down for 5 minutes, and 18 µl aliquots of the supernatants were taken separately for Western blot analysis. The remaining supernatants were incubated with 2 µl of rabbit anti-GFP-antibody (Molecular Probes, Eugene, OR) at 4°C for one hour before the immuncomplexes were captured using EZview Red Protein G Affinity Gel (Sigma) at 4°C over-night.
After washing the agarose beads twice with washing buffer containing Igepal CA-630 (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 2 mM EDTA, 0.1% Igepal), twice with 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  R  e  v  i  e  w  O  n  l  y   21 washing buffer without Igepal and once with kinase buffer, GFP-DYRK1A was assayed in vitro for kinase activity. The assays were carried out at 30°C for 30 min in a total reaction volume of 30 µl as described above, except that here we used a concentration of 10 µM ATP. After washing the immunoprecipitates with Igepal-free washing buffer, the bound proteins were eluted with sample buffer, separated by SDS-PAGE (8%) and blotted onto nitrocellulose membranes. The membranes were subjected to Western blot analysis as indicated in the figure legends.
In vitro translation of DYRK1A
An expression plasmid for FLAG-tagged mouse DYRK1A with a T3 promotor sequence upstream of the open reading frame (pCMV-Tag2A-FLAG-DYRK1A) was kindly provided by Beat Lutz (Johannes Gutenberg Universität Mainz, Germany). 
Analysis of quantitative data
The GraphPad Prism 5.0 program (GraphPad Software, La Jolla, CA) was used for curve fitting by nonlinear regression and statistical analysis. The data generated in in vitro kinase assays were fitted to a one-site inhibition model (to a "dose-response curve -inhibition") with a Hill slope of -1 or a variable Hill slope (Y=100/(1+10^((XLogIC50))); or for variable slope: Y=100/(1+10^((LogIC50-X)*HillSlope))) ). For each data set, the model with the best fit was determined with the extra sum of squares F test (p<0.05). For quantitative evaluation of the HeLa cell experiment (Fig. 3) , band intensities were fitted to a "dose-response curve -inhibition" with a Hill slope of -1. 21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 B, Aliquots of the cell lysates were analyzed for phosphorylation of endogenous SF3B1 at Thr434 to confirm the efficacy of the harmine treatment. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 The activities were normalized to DYRK1A immunoreactivity. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
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